Adaptimmune Therapeutics
ADAP
$1.19
Share price
-1.65%
Change (1 day)
-13.14%
Change (1 year)
Categories
Adaptimmune Therapeutics (ADAP) - Net assets
Net assets on the balance sheet as of December 2023 : $39.51 M
According to Adaptimmune Therapeutics's latest financial reports the company has $39.51 M in net assets.
A company’s net assets is the sum of its assets minus the sum of its liabilities.
Adaptimmune Therapeutics - Net assets on balance sheet (from 2014 to 2023)
Net assets by year
| Year | Net assets | Change |
|---|---|---|
| 2023-12-31 | $39.51 M | -51.74% |
| 2022-12-31 | $81.87 M | -60.25% |
| 2021-12-31 | $0.20 B | -39.64% |
| 2020-12-31 | $0.34 B | 175.99% |
| 2019-12-31 | $0.12 B | -49.92% |
| 2018-12-31 | $0.24 B | 21.63% |
| 2017-12-31 | $0.20 B | 22.18% |
| 2016-12-31 | $0.16 B | |
| 2015-06-30 | $0.25 B | 10647.07% |
| 2014-06-30 | $2.4 M | -211.8% |
| 2013-06-30 | $-2.16 M | 1615.51% |
| 2012-06-30 | $-0.13 M |
Net assets for similar companies or competitors
| Company | Net assets | differencediff. | Country |
|---|---|---|---|
 uniQure QURE | $0.20 B | 425.57% | 🇳🇱 Netherlands |
 Novavax NVAX | -$0.72 B | -1,914.41% | 🇺🇸 USA |
 Exelixis EXEL | $2.26 B | 5,629.53% | 🇺🇸 USA |
 Enzo Biochem ENZ | $70.77 M | 79.12% | 🇺🇸 USA |